Low-level laser therapy induces dose-dependent reduction of TNFα levels in acute inflammation

Photomedicine and Laser Surgery

Volumn 24, Issue 1, 2006, Pages 33-37

  Aimbire, F ^a   Albertini, R ^a   Pacheco, M T T ^a   Castro Faria Neto, H C ^b   Leonardo, P S L M ^c   Iversen, V V ^d   Lopes Martins, Rodrigo Alvaro Brandão ^c   Bjordal, J M ^d  

^a INSTITUTO DE PESQUISA E DESENVOLVIMENTO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; FLAMMABILITY; IMMUNOLOGY; LASERS; MEDICINE; PULMONARY DISEASES; TUMORS;

LOW-LEVEL LASER THERAPY (LLLT); OVALBUMIN; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR;

LASER APPLICATIONS;

ALUMINUM; ARSENIC; CHLORPROMAZINE; GALLIUM; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; GALLIUM ALUMINUM ARSENIC LASER; IMMUNE COMPLEX DISEASE; IMMUNE MEDIATED INJURY; INFLAMMATION; LASER; LOW LEVEL LASER THERAPY; LUNG INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RAT; RHEUMATOID ARTHRITIS;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; INFLAMMATION; LASER THERAPY, LOW-LEVEL; LUNG; MALE; MODELS, ANIMAL; RADIOTHERAPY DOSAGE; RATS; RATS, WISTAR; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645238723     PISSN: 15495418     EISSN: None     Source Type: Journal    
DOI: 10.1089/pho.2006.24.33     Document Type: Article

References (35)

1. Goldman, J.A. (1981). Investigative studies of laser technology in rheumatology and immunology, in: Biomedical Laser Technology-Clinical Applications. New York: Springer Verlag.
2. Basford, J.R. (1993). Laser therapy: scientific basis and clinical role. Orthopedics 16, 541-547.
3. Beckerman, H., Bie, R.A., Bouter, L.M., et al. (1992). The efficacy of laser therapy for musculoskeletal and skin disorders: a criteria-based meta-analysis of randomized clinical trials. Phys. Ther. 72, 483-491.
4. Brosseau, L., Welch, V., Wells, G., et al. (2000). Low-level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 2.
5. Bouma, M.G., Buurman, W.A., Wildenberg, F.A., et al. (1996). Low-energy laser irradiation fails to modulate the inflammatory function of human monocytes and endothelial cells. Lasers Med. Surg. 19, 207-215.
6. 2 and interleukin 1 beta production by low-power laser irradiation in stretched human periodomal ligament cells. J. Dental Res. 74, 1382-1388.
7. Sakurai, Y., Yamaguchi, M., and Abiko, Y. (2000). Inhibitory effect of low-level laser irradiation on LPS-stimulated prostaglandin E2 production and cyclooxygenase-2 in human gingival fibroblasts. Eur. J. Oral Sci. 108, 29-34.
8. Campana, V., Moya, M., Gavotto, A., et al. (1999). The relative effects of HeNe laser and meloxicam on experimentally induced inflammation. Laser Ther. 11, 36-41.
9. Albertini, R., Aimbire, F.S., Correa, F.I., et al. (2004). Effects of different protocol doses of low-power gallium-aluminum-arsenate (Ga-Al-As) laser radiation (650 nm) on carrageenan induced rat paw ooedema. J. Photochem. Photobiol. B 74, 101-107.
10. Naidu, B.V., Woolley, S.M., Farivar, A.S., et al. (2004). Early tumor necrosis factor-alpha release from the pulmonary macrophage in lung ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 127, 1502-1508.
11. Hakonarson, H., Maskeri, N., Carter, C., et al. (1999). Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J. Clin. Invest. 103, 1077-1087.
12. McKay, S., Hirst, S.J., Haas, M.B., et al. (2000). Tumor necrosis factor-alpha enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 23, 103-111.
13. Ravetch, J.V., and Kinet, J.P. (1991). Fc receptors. Annu. Rev. Immunol. 9, 457-492.
14. Sampson, A.P. (2000). The role of eosinophils and neutrophils in inflammation. Clin. Exp. Allergy 30, 22-27.
15. beta- but not TNF-alpha-induced neutrophil transmigration in vivo. J. Leukoc. Biol. 77, 159-165.
16. Song, H., Li, G., Ye, J., et al. (2004). Immunomodulating effects of cefodizime on Klebsiella pneumoniae-stimulated neutrophils. Immunobiology 209, 277-282.
17. Ghaffar, O., Hamid, Q., Renzi, P.M., et al. (1999). Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 159, 1933-1942.
18. Souza, D.G., Soares, A.C., Pinho, V., et al. (2002). Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am. J. Pathol. 160, 1755-1765.
19. Scott, D.L. (2005). Etanercept in arthritis. Int. J. Clin. Pract. 59, 114-118.
20. Warren, J.S., Yabroff, K.R., Remick, D.G., et al. (1989). Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J. Clin. Invest. 84, 1873-1882.
21. Tavares de Lima, W., Steil, A.A., Russo, M., et al. (1998). Lipid mediators, tumor necrosis factor and nitric oxide and their interactions in immune-complex-induced lung injury. Eur. J. Pharmacol. 358, 69-75.
22. Mulligan, M.S., and Ward, P.A. (1992). Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1. J. Immunol. 149, 331-339.
23. alpha-induced suppression of PMN apoptosis is mediated through interleukin-8 production. Shock 14, 284-289.
24. Johnson, K.J., Wilson, B.S., Till, G.O., et al. (1984). Acute lung injury in rat caused by immunoglobulin A immune complexes. J. Clin. Invest. 74, 358-369.
25. Mulligan, M.S., Jones, M.L., Vaporciyan, A.A., et al. (1993). Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J. Immunol. 151, 5666-5674.
26. Mulligan, M.S., Yeh, C.G., Rudolph, A.R., et al. (1992). Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J. Immunol. 148, 1479-1485.
27. Cuzzocrea, S., Mazzon, E., Sautebin, L., et al. (2002). Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem. Pharmacol. 63, 785-795.
28. Stadler, I., Lanzafame, R.J., Oskoui, P., et al. (2004). Alteration of skin temperature during low-level laser irradiation at 830 nm in a mouse model. Photomed. Laser Surg. 22, 227-231.
29. Karu, T. (1989). Photobiology of low-power laser effects. Health Phys. 56, 691-704.
30. Kandolf-Sekulovic, L., Kataranovski, M., and Pavlovic, M.D. (2003). Immunomodulatory effects of low-intensity near-infrared laser irradiation on contact hypersensitivity reaction. Photodermatol. Photoimmunol. Photomed. 19, 203-212.
31. Shefer, G., Oron, U., Irintchev, A., et al. (2001). Skeletal muscle cell activation by low-energy laser irradiation: a role for the MAPK/ERK pathway. J. Cell Physiol. 187, 73-80.
32. Campana, V., Moya, M., Gavotto, A., et al. (2003). He-Ne laser on microcrystalline arthropathies. J. Clin. Laser Med. Surg. 21, 99-103.
33. Bjordal, J., Couppé, C., and Ljunggreen, A. (2001). A literature review of possible effective intervals of red and infrared irradiation for enhanced tissue repair in the human locomotor system. Presented at the 9th Congress of European Society for Photobiology.
34. Giuliani, A., Fernandez, M., Farinelli, M., et al. (2004). Very low level laser therapy attenuates edema and pain in experimental models. Int. J. Tissue React. 26, 29-37.
35. Karu, T., Pyatribat, L.V., et al. Ryabykh, T. (1997). Nonmonotonic behaviour of the dose dependence of the radiation effect on cells in vitro exposed to pulsed laser radiation at 820-nm wavelength. Lasers Med. Surg. 21, 485-492.